Kyowa Kirin Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Kyowa Kirin Stock Forecast and Price Target
The average price target of ¥3000.00 for Kyowa Kirin's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 14.33% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of ¥3800.00 and a low estimate of ¥2500.00. If you are interested in 4151 stock, it is important to also consider its competitors.
14.33% Upside
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF218.80 | Buy/Sell | CHF307.83 | 24.54% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.41 | Buy/Sell | £17.30 | 18.83% |
| SGEN Stock Forecast | Seattle Genetics Inc | - |
16
|
$228.74 | Buy/Sell | $225.41 | 0.11% |
Kyowa Kirin Revenue Forecast for 2023 - 2025 - 2030
Kyowa Kirin's Revenue has grown In the last two years, rising from ¥318.35B to ¥398.37B – a growth of 25.14%. According to the 0 analysts polled, in the next year, Kyowa Kirin's Revenue will fall by 10.93%, reaching ¥354.84B. By 2030, professionals believe that Kyowa Kirin's Revenue will have decreased by 10.30%, falling to ¥357.34B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.62 | Buy/Sell | $9.50 | 10.21% |
| 600267 Stock Forecast | Zhejiang Hisun Pharmaceutical | Hold |
11
|
¥7.87 | Buy/Sell | ¥15.60 | 5.46% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.31 | Buy/Sell | $41.00 | 36.47% |
.jpg)
Kyowa Kirin Dividend per Share Forecast for 2023 - 2025 - 2030
Kyowa Kirin's Dividend per Share has seen impressive growth In the last two years, rising from ¥44.00 to ¥51.00 – a growth of 15.91%. For the next year, 0 analysts project Kyowa Kirin's Dividend per Share to drop by 7.98%, reaching ¥46.93. By 2030, professionals believe that Kyowa Kirin's Dividend per Share will decrease by 7.67%, reaching ¥47.09 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| URGN Stock Forecast | UroGen Pharma | Outperform |
6
|
$13.82 | Buy/Sell | $39.00 | 196.67% |
| HRTX Stock Forecast | Heron Therapeutics | Buy |
7
|
$2.55 | Buy/Sell | $5.63 | 154.90% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.43 | Buy/Sell | $200.00 | -100.00% |
Kyowa Kirin EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Kyowa Kirin's EBITDA has grown, moving from ¥74.71B to ¥99.30B – an increase of 32.92%. In the following year, 0 experts forecast Kyowa Kirin's EBITDA will decrease by 15.20%, to ¥84.21B. In 2030, professionals predict that Kyowa Kirin's EBITDA will decrease by 14.02%, to ¥85.38B.
Kyowa Kirin EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Kyowa Kirin's EBIT has seen an increase, rising from ¥54.24B to ¥80.83B. This represents a growth of 49.02%. According to 0 major analysts, Kyowa Kirin's EBIT will fall by 20.26% in the next year, reaching ¥64.45B. Professionals believe that By 2030, Kyowa Kirin's EBIT will fall to ¥66.20B– a 18.09% decrease from its current value.
.jpg)